Document is current
Any future updates will be listed below
-
Authors
Brown, Thomas https://orcid.org/0000-0001-8293-4816
Howe, Françoise S
Murray, Struan C
Wouters, Meredith
Lorenz, Philipp https://orcid.org/0000-0001-5005-2114
Seward, Emily https://orcid.org/0000-0002-7869-0641
Rata, Scott
Angel, Andrew https://orcid.org/0000-0003-0075-1480
Mellor, Jane https://orcid.org/0000-0002-5196-3734
-
Funding
Funding for this research was provided by:
Wellcome (WT089156MA)
Leverhulme Trust (RPG‐2016‐405)
Royal Society (UF120327)
RCUK | Biotechnology and Biological Sciences Research Council (BB/P00296X/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/J014427/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/M011224/1)
RCUK | Engineering and Physical Sciences Research Council (EP/F500394/1)
RCUK | Engineering and Physical Sciences Research Council (EP/G03706X/1)
European Union Seventh Framework Programme (EpiGeneSys)
- License Information
-
More Information
Article History
Received: 26 September 2017
Revised: 13 January 2018
Accepted: 16 January 2018
First Online: 12 February 2018
Conflict of interest
: JM acts as an advisor to and holds stock in Oxford Biodynamics plc., Chronos Therapeutics Ltd., and Sibelius Natural Products Ltd.
